Home > Browse Research > Life Sciences > Pharmaceuticals > Biopharmaceuticals > Biosimilars

Biosimilars: market research reports

Biosimilars or biogenerics, are generic non-patented chemical and therapeutic equivalents of brand name biopharmaceutical drugs. Biopharmaceuticals are synthetic or recombinant versions of natural biologic substances, including proteins such as enzymes or antibodies, and nucleic acids such as DNA or RNA. However, biogenerics are not generic biologics because there can be no generic form of biologics due to the complex process of creating biologics.

Industry participants are struggling with what to call these hybrid forms of biologics that will be created by the generic companies.

The worldwide prescription generic drug market has stood the test of time and has endured numerous growing pains. However, it has evolved into a formidable and important participant in the complex world of health care. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market.

Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for the promotion of biosimilars is favorable in the next five years.

Biosimilars market research reports and industry analysis

Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors 5/1/2013 \| published by: La Merie Publishing ... and development pipelines of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated and less regulated markets: Erythropoiesis Stimulating Agents (ESA) G-CSF & GM-CSF Thrombopoietin & Thrombopoiesis Stimulating Agents Interferon ... \| read more...	$2,100.00
Russia Generics and Biosimilars 3/1/2013 \| published by: Datamonitor ... industry threaten to change the market landscape and will prompt a change in tactics by foreign branded manufacturers looking to maintain their lead. Features and benefits Contains key market metrics to help you identify trends ... \| read more...	$1,900.00
Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion 1/31/2013 \| published by: GBI Research ... research, “Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion”. The currently marketed monoclonal antibodies are clinically and commercially highly successful ... \| read more...	$3,500.00
Italy Pharmaceutical Market Overview – Challenging outlook due to austerity and falling birth rate 12/7/2012 \| published by: Datamonitor ... payers seek to control healthcare spending, generic uptake will increase. Features and benefits Analysis of population demographics, economic indicators, and political developments in Italy. Insight into the healthcare system, drug regulation, drug pricing, drug reimbursement, ... \| read more...	$5,700.00
Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies 12/1/2012 \| published by: La Merie Publishing ... as biosimilar versions as of December 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the ... \| read more...	$1,307.00
Competitor Analysis: EGF-R Antibodies –Biosimilars and Biosuperiors 12/1/2012 \| published by: La Merie Publishing ... Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and ... \| read more...	$261.00
2012 Biotechnology Research Review 12/1/2012 \| published by: BCC Research ... that have entered the market worldwide and forecasts the growth prospects for these products. A detailed analysis of the kinase inhibitors industry structure has been conducted. Revenues are broken down by region. Sales figures are ... \| read more...	$950.00
Competitor Analysis: TNF Antibodies –Biosimilars and Biosuperiors 11/30/2012 \| published by: La Merie Publishing ... and autoimmune diseases as of November 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the ... \| read more...	$523.00
Global Biosimilars Market - Products, Applications and Regulations 11/26/2012 \| published by: Industry Experts ... to be challenged over the next ten years, since the rapid growth forecast for the biosimilars market has attracted several new companies to enter this lucrative arena. Current leaders, in order to maintain market share, ... \| read more...	$4,320.00
Taiwan - Mobile Market - Overview, Statistics and Forecasts 11/20/2012 \| published by: Paul Budde Communication Pty Ltd ... the market took over three years to reach the ‘one million subscribers’ but increasing competition and increasing handset and applications availability put the market into overdrive. By 3Q 2012 there were close to 22 million ... \| read more...	$200.00
How Will the Launches of Oral Immunomodulators and Biosimilars Shape the EU5 Prescribing and Reimbursement Landscape for Current and Emerging Biologics in Rheumatoid Arthritis? 11/16/2012 \| published by: Decision Resources ... include five tumor necrosis factor-alpha (TNF-a) inhibitors, Bristol-Myers Squibb’s selective costimulation modulator Orencia, Roche’s MabThera (Roche/Biogen Idec Chugai/Zenyaku Kogyo’s B-cell inhibitor Rituxan), and the more recently launched interleukin-6 (IL-6) inhibitor Actemra/RoActemra from Roche/Chugai. However, two ... \| read more...	$10,000.00
Cell Culture - Rising Demand for Biologics and Growing Visibility of Approval Pathway for Biosimilars will Create Growth Opportunities 11/9/2012 \| published by: GBI Research ... Rising Demand for Biologics and Growing Visibility of Approval Pathway for Biosimilars will Create Growth Opportunities”, which provides in-depth analysis on the processes, drivers and barriers of the cell culture market. The report analyzes the ... \| read more...	$3,500.00
Global Healthcare Cold Chain Logistics Market Report & Forecast: 2012-2017 11/5/2012 \| published by: IMARC ... firms, finds that the total size of the healthcare cold chain logistic services market is expected to expand from its current figures of US$ 6.7 billion to nearly US$ 10.7 billion by 2017. This report, ... \| read more...	$1,200.00
Competitor Analysis: VEGF Antibodies – Bevacizumab and Ranibizumab Biosimilars and Biosuperiors 11/1/2012 \| published by: La Merie Publishing ... cancers and ophthalmic diseases as of November 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access ... \| read more...	$392.00
Competitor Analysis: Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors 11/1/2012 \| published by: La Merie Publishing ... of November 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent ... \| read more...	$392.00
Biosimilars Advisory Service: Physician Perspectives on Biosimilar G-CSF's and Monoclonal Antibodies in Oncology 10/19/2012 \| published by: Decision Resources ... primary research and forecasting modules are all included in a subscription to the Biosimilars Advisory Service. Rely on BioTrends to keep you up-to-date on the biosimilars landscape and poised to maximize opportunities for your business. ... \| read more...	$10,000.00
Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors 10/1/2012 \| published by: La Merie Publishing ... arthritis as of October 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will ... \| read more...	$390.00
Global Biosimilars Industry 10/1/2012 \| published by: Taiyou Research ... caliber in US and five major European nations for biosimilars was $150.4 million and expanded to $198 million in the next 12 months which followed. It is also greatly anticipated that by 2015 the market ... \| read more...	$850.00
Global Biotechnology Market 10/1/2012 \| published by: Taiyou Research ... economy. The products derived through biotechnology have altered the landscape of many industries, particularly pharmaceuticals. The completion of the Human Genome Project has been a huge milestone in the biotechnology industry as it has become ... \| read more...	$850.00
Biosimilars Advisory Service: Physician Perspectives on Erythropoietin Stimulating Agents, Insulin and Human Growth Hormone 9/27/2012 \| published by: Decision Resources ... primary research and forecasting modules are all included in a subscription to the Biosimilars Advisory Service. Rely on BioTrends to keep you up-to-date on the biosimilars landscape and poised to maximize opportunities for your business. ... \| read more...	$10,000.00
Biosimilars Advisory Service: Physician Perspectives on Pegylated IFN-a and TNF-a Inhibitors in Immune and Infectious Disease 9/19/2012 \| published by: Decision Resources ... primary research and forecasting modules are all included in a subscription to the Biosimilars Advisory Service. Rely on BioTrends to keep you up-to-date on the biosimilars landscape and poised to maximize opportunities for your business. ... \| read more...	$10,000.00
How Will Reimbursement Decisions for Novel Biologics and Biosimilars Impact Prescribing in the Dynamic Markets for Crohn’s Disease and Ulcerative Colitis? 8/28/2012 \| published by: Decision Resources ... marketed biologic. In both CD and UC, Janssen Biotech’s Remicade (infliximab) continues to dominate the U.S. market and stand as the therapy to beat for agents positioned in the segment of the market for patients ... \| read more...	$10,000.00
Strategies for Comparative Efficacy Trials 8/23/2012 \| published by: Datamonitor ... role of comparative efficacy trials and the challenges in their design, with particular attention to the question of comparator selection. Introduction Understand the role that comparative efficacy plays in the evaluation of new drugs. Review ... \| read more...	$3,800.00
Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key Growth Region 8/22/2012 \| published by: GBI Research ... Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key Growth Region provides detailed insight into the Americas API market. The research presents detailed ... \| read more...	$3,500.00
Plunkett's Biotech & Genetics Industry Almanac 2013: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies 8/22/2012 \| published by: Plunkett Research, Ltd. ... -Industry Glossary -Buyer may register for access to search and export data at Plunkett Research Online Pages: 537 Statistical Tables Provided: 18 Companies Profiled: 353 Geographic Focus: Global A complete market research report, including forecasts ... \| read more...	$349.99

< prev 1 2 3 4 5 next >